Company
Investment-firm
Last deal
Amount
Stage
Date
all rounds
Total amount
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
Karyopharm Therapeutics
Karyopharm Therapeutics is a clinical-stage pharmaceutical company developing drugs for cancer and other major diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Cardior Pharmaceuticals
Cardior Pharmaceuticals develops innovative RNA-based therapeutics to prevent and treat heart disease.
Sector
Subsector
Location
total rounds
total raised
Axys Pharmaceuticals
AXYS Pharmaceuticals develops small molecule therapeutics for chronic diseases, cancer, and other specialty therapeutic opportunities.
Sector
Subsector
Keywords
Location
total rounds
total raised
Sierra Oncology
Sierra Oncology is a late-stage biopharmaceutical company focused on developing targeted therapies for rare forms of cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds15
Number of Funding Rounds
Money Raised
Their latest funding was raised on 28.02.2024. Their latest investor GordonMD Global Investments. Their latest round Post-IPO Equity
Investments2
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on developing novel radiotherapeutics for oncology treatment.
Sector
Subsector
Keywords
Location
total rounds
total raised
Radionetics Oncology
Radionetics Oncology is a pharmaceutical company focused on developing novel radiotherapeutics for oncology treatment.
Sector
Subsector
Keywords
Location
total rounds
total raised
Co-Investors
Investors20
Number of lead investors
Number of investors
GordonMD Global Investments
GordonMD Global Investments is a private equity firm that invests in innovative biopharma companies worldwide.
Sector
Subsector
Keywords
Location
count Of Investments
Driehaus Capital Management
Driehaus is an investment management firm that manages growth equity investment strategies and multi-asset alternative strategies.
Sector
Subsector
Location
count Of Investments
count Of Exists
EcoR1 Capital
EcoR1 Capital is a biotech-focused investment advisory firm based in San Francisco.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders3
Stephen F. Betz
Stephen F. Betz (Vice President, Biology) is a Founder of Crinetics Pharmaceuticals. He earned his Ph.D. in Chemistry from the University of North Carolina at Chapel Hill where he studied protein structure and stability. He pursued postdoctoral studies in the laboratory of William DeGrado at the DuPont Merck Pharmaceutical Company where he focused on protein engineering and de novo design. He moved to pharmaceutical discovery in the Research NMR Group at Abbott Laboratories, working on protein structure, structure-guided drug design, assay development, and compound screening in several different therapeutic areas. Subsequently, he led laboratory efforts at GeneFormatics, a biotechnology company founded on protein function annotation and characterization. Most recently, he was Director of Endocrinology and Metabolism at Neurocrine Biosciences working on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets.
current job
Stephen F. Betz
Yun-Fei Zhu
Yun-Fei (Frank) Zhu (Vice President, Chemistry) is a Founder of Crinetics Pharmaceuticals. He received his Ph.D. in Organic Chemistry from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences in China, and pursued his postdoctoral studies in the laboratory of Professor Murray Goodman in Department of Chemistry, University of California, San Diego. He joined Neurocrine Biosciences in 1997 where he led chemistry efforts on discovery of nonpeptide GnRH antagonists. He was most recently a Director of Chemistry in the Endocrinology and Metabolism group. His research has involved discovery of small molecule inhibitors of several neuropeptide receptors including CRFR2, MCH receptor, and GnRH-R for the treatment of a range of endocrine diseases.
current job
organization founded
Yun-Fei Zhu
Scott Struthers
R. Scott Struthers (CEO & Chief Scientific Officer) is a Founder of Crinetics Pharmaceuticals. Dr. Struthers received his Ph.D. in Physiology and Pharmacology from the University of California, San Diego, under the supervision of Professor Wylie Vale. Following his degree, he led contract research efforts at Biosym Technologies developing and applying computational tools for drug discovery. He then cofounded ScienceMedia Inc. to develop eLearning solutions for the life sciences and higher education markets. From 1998 to 2008 he held a series of positions at Neurocrine Biosciences, most recently as Senior Director and Head, Endocrinology and Metabolism. There he initiated and led the company’s efforts to discover and develop orally active, nonpeptide GnRH antagonists. This resulted in a first-in-class compound, elagolix, that has demonstrated good safety and efficacy in over 40 clinical trials totaling more than 3000 patients including a 6-month, 872 patient recently completed Phase III study. In 2008, he founded Crinetics Pharmaceuticals to focus on discovery and development of drugs targeting neuropeptide receptors for the treatment of endocrine related diseases and cancers. Dr. Struthers is an author of more than 75 scientific publications.
current job
organization founded
Scott Struthers
Employee Profiles18
Dana Jennings
Senior manager, contracts and procurement
Dana Rilatos
Senior manager, contracts and procurement
Activity
Recent News33
The graph reveals the ratio (%) of positive news articles in a chosen time range